Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

CRIXIVAN

INDINAVIR SULFATE

Standard Dose
EQ 200MG BASE
Max Dose
Refer to approved labeling
Primary Use
Review priority: 901 REQUIRED Marketing status: Discontinued
Summary

Approval overview CRIXIVAN is listed in Drugs@FDA under application 020685 (NDA).

Review priority: 901 REQUIRED Marketing status: Discontinued Active ingredient INDINAVIR SULFATE Form and strength CAPSULE;ORAL - EQ 200MG BASE Sponsor MERCK SHARP DOHME Submission history Latest submission status date: 2016-09-15 00:00:00.

Structured Monograph

Clinical summary

Approval overview CRIXIVAN is listed in Drugs@FDA under application 020685 (NDA). Review priority: 901 REQUIRED Marketing status: Discontinued Active ingredient INDINAVIR SULFATE Form and strength CAPSULE;ORAL - EQ 200MG BASE Sponsor MERCK SHARP DOHME Submission history Latest submission status date: 2016-09-15 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: 901 REQUIRED

Interaction Notes

  • No interaction notes stored yet.